This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
Deep diveMEDTECH

Gut Microbiome Precision Regulation Therapy Platform MicrobiomeRx Deep Dive: Using Bacteriophages to Precisely Edit the Gut Microbiome

Israeli biotech company Biomica's MicrobiomeRx platform uses AI-designed engineered bacteriophages to precisely eliminate harmful gut bacteria and promote beneficial colonization, showing significant efficacy in inflammatory bowel disease treatment.

Gut Microbiome Precision Regulation Therapy Platform MicrobiomeRx Deep Dive: Using Bacteriophages to Precisely Edit the Gut Microbiome

On January 6, 2031, Israeli biotechnology company Biomica released MicrobiomeRx — a therapeutic platform that uses AI-designed engineered bacteriophages to precisely regulate the gut microbiome. Unlike traditional broad-spectrum antibiotics and probiotics, MicrobiomeRx can "edit" the composition of gut flora much like gene editing.

MicrobiomeRx's workflow consists of three steps: first, analyzing the complete composition of the patient's gut microbiome through metagenomic sequencing; then using AI algorithms to identify harmful bacterial strains that need to be eliminated and beneficial strains that need to be promoted; and finally, designing a customized bacteriophage cocktail that precisely targets specific strains without affecting other microorganisms.

In a Phase II clinical trial for inflammatory bowel disease (IBD), MicrobiomeRx achieved a clinical remission rate of 62% in 86 patients — three times that of the placebo group. More importantly, patients' gut microbiome diversity index increased by an average of 40% after treatment.

"The gut microbiome is like a complex ecosystem," explained Eran Elinav, head of microbiome research at the Weizmann Institute of Science. "What's revolutionary about MicrobiomeRx is that it doesn't simply use antibiotics to 'tear everything down and start over' — it precisely regulates the microbiome like a gardener pruning a garden."

Biomica CEO Jonathan Solomon revealed that the company has secured $250 million in Series C funding to advance MicrobiomeRx's clinical trials in metabolic diseases and neurodegenerative diseases.

However, one of the challenges facing phage therapy is bacterial resistance evolution. Biomica says its AI platform can predict possible bacterial resistance mutation pathways and design countermeasures in advance.